Study of the safety and effectiveness of tolDC therapy in patients with progressive forms of multiple sclerosis

2 1 1

What is this study about?

This study focuses on individuals living with progressive forms of Multiple Sclerosis, a condition that affects the central nervous system. The research aims to evaluate the safety and effectiveness of a treatment called tolDC. This therapy involves using tolerogenic dendritic cells, which are specialized immune cells that are modified to help the body stop attacking its own healthy tissues. These cells are prepared using vitamin D3 and pieces of myelin, which is the protective coating around nerve fibers that is often damaged in this disease.

The treatment is administered through an intradermal injection, which is an injection delivered into the skin. During the course of the study, participants will undergo various assessments to monitor how they respond to the therapy. This includes regular neurological examinations and the use of MRI to look for changes in the brain, such as new or growing lesions, which are areas of damage. Additionally, blood samples may be collected to measure specific biomarkers, which are natural substances in the body that provide information about the state of the disease and how the body is reacting to the treatment.

Who Can Join the Study?

You must be between 18 and 65 years old at the time of the first screening visit.
You must have a confirmed diagnosis of Multiple Sclerosis (a condition affecting the central nervous system) based on specific medical standards known as the McDonald Criteria.
You must have a progressive form of the disease, meaning the condition worsens over time without distinct periods of recovery.
Your disability level, measured by the Expanded Disability Severity Scale (EDSS)—which is a scale used to measure how much the disease affects your ability to walk and function—must be between 2.0 and 7.5.
You must not have had any relapses (sudden increases in symptoms or new neurological problems) in the last 2 years.
You must be able to understand the study details and be willing to sign a written informed consent document, which is a formal paper stating you agree to participate after being fully informed.
You must have appropriate venous access, meaning you have veins that are suitable for medical procedures like blood draws or giving medication.
You must use effective birth control or not be at a stage in life where you can become pregnant.

Who Cannot Join the Study?

You have used certain medications, such as alemtuzumab, autologous hematopoietic stem cell transplantation (a procedure where a person’s own blood-forming stem cells are collected and then returned to the body), or cladribine within the last 3 years.
You have an active or long-term infection with hepatitis B, hepatitis C, HIV (a virus that attacks the body’s immune system), syphilis, or tuberculosis.
You have had a splenectomy, which is the surgical removal of the spleen.
You have dementia (a decline in mental ability) or severe issues with mental health, thinking, or behavior that might make it difficult to follow the study rules.
You have taken any experimental medicine within the last 3 months, or within a timeframe determined by how long the medicine stays in your body (known as 5 half-lives).
You are currently taking an approved DMT (disease-modifying therapy), which is a medicine used to change the course of multiple sclerosis.
You have used specific medicines like S1P receptor modulators, natalizumab, dimethylfumarate, or teriflunomide within the last 3 months.
You have used B cell depleting monoclonal antibodies (medicines that reduce certain immune cells) within the last 6 months, or if your CD19 B cell counts (a measure of specific immune cells in your blood) are not normal.
You are pregnant, breastfeeding, or planning to become pregnant within the next 12 months.
You have a history of drug or alcohol abuse.
You are unable to undergo an MRI (a medical imaging test that uses strong magnets to create detailed pictures of the inside of the body).
You have a history of or current signs of immunodeficiency (a weakened immune system) or malignancies (cancer), unless it is a treated basal cell carcinoma (a common, slow-growing type of skin cancer).
You have other major health problems involving the heart, immune system, lungs, nervous system, or kidneys that could affect your safety or the results of the study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Uwhtnlzzbb Oh Aofilhx	Edegem	Belgium
Hzzleqkd Ujjztfzbrrxmf Hvtbrybo Tdpcl y Prwydn Ihpkexuf Cravto dfffxglasrqtwmvly (kueg	Badalona	Spain

Trial status

Country	Status	Recruitment Start
Belgium	Not yet recruiting	02.03.2026
Spain	Not yet recruiting	02.03.2026

Trial locations

Investigated drugs:

Toldc

tolDC is a specialized cell therapy made from the patient’s own immune cells. These cells are treated with vitamin D3 and loaded with specific pieces of myelin (the protective coating around nerve cells) to help train the immune system to stop attacking the nervous system in people with progressive multiple sclerosis.

Investigated diseases:

Multiple sclerosis

Multiple Sclerosis – This is a condition where the body’s immune system attacks the protective covering that surrounds nerve cells in the brain and spinal cord. This process causes damage to the nerves and disrupts the communication signals between the brain and the rest of the body. As the condition progresses, it can lead to a steady increase in physical disability. It often involves various neurological changes that affect movement and coordination. The progression can occur in different patterns, including stages where symptoms worsen over time.

Trial ID:

2025-522040-40-01

NCT ID:

NCT07020715

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study of the safety and effectiveness of tolDC therapy in patients with progressive forms of multiple sclerosis

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?